All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

clenbuterol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
bronchodilators, phenethylamine derivatives	673	37148-27-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clenbuterol (RS)-Clenbuterol (+/-)-Clenbuterol planipart dl-Clenbuterol clenbuterol hydrochloride clenbuterol HCl	A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. Molecular weight: 277.19 Formula: C12H18Cl2N2O CLOGP: 2.39 LIPINSKI: 0 HAC: 3 HDO: 3 TPSA: 58.28 ALOGS: -3.39 ROTB: 4

Drug dosage:

Dose	Unit	Route
40	mcg	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	4 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	0.578		Moderate	0.67
caco2-efflux	Caco-2 efflux ratio (BA/AB)	1.419		Moderate	0.67
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	9.954	10^-6 cm/s	Moderate	0.67
dh-clint	Dog hepatocyte intrinsic clearance	3.954	uL/min/10^6 cells	Moderate	0.67
dppb	Dog plasma protein binding (% unbound)	65.060	%	Moderate	0.67
fcs-ppb	Fetal calf serum protein binding (% unbound)	66.670	%	Moderate	0.67
herg	hERG pIC50	4.430	pIC50	Moderate	0.67
hh-clint	Human hepatocyte intrinsic clearance	2.249	uL/min/10^6 cells	Moderate	0.67
hlm-clint	Human liver microsomal intrinsic clearance	3.436	uL/min/mg protein	Moderate	0.67
hppb	Human plasma protein binding (% unbound)	66.250	%	Moderate	0.67
kinase-safety-class	ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ZAP70	49
kinase-selectivity-class	AXL,EIF2AK3,GRK2,PDK4	4
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	3.475		Moderate	0.67
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	2.254		Moderate	0.67
mh-clint	Mouse hepatocyte intrinsic clearance	27.733		Moderate	0.67
mppb	Mouse plasma protein binding (% unbound)	66.510		Moderate	0.67
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	3.027		Moderate	0.67
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	70.860	%	Moderate	0.67
rat-kpuu-brain	Rat brain Kpuu	0.093	%	Moderate	0.67
rh-clint	Rat hepatocyte intrinsic clearance	28.314	uL/min/10^6 cells	Moderate	0.67
rh-fuinc	Rat hepatocyte fraction unbound in incubation	83.560	%	Moderate	0.67
rppb	Rat plasma protein binding (% unbound)	66	%	Moderate	0.67
solubility-dd	Solubility at pH 7.4 in DMSO	901.571	uM	Moderate	0.67

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional product misuse	88.25	63.58	31	547	132873	110455848
Hyperthyroidism	73.09	63.58	19	559	29242	110559479
Myocarditis	67.78	63.58	18	560	30037	110558684

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R03AC14	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Selective beta-2-adrenoreceptor agonists
ATC	R03CC13	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Selective beta-2-adrenoreceptor agonists
ATC	R03CC63	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Selective beta-2-adrenoreceptor agonists
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D013566	Sympathomimetics
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D019141	Respiratory System Agents
CHEBI has role	CHEBI:35522	β-adrenergic agonist
CHEBI has role	CHEBI:35523	bronchodilator agent
CHEBI has role	CHEBI:35524	sympathomimetic agent
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:48407	antiparkinson drug

Related Drugs by ATC class:

R03AC Selective beta-2-adrenoreceptor agonists 17 drugs

bitolterolcarbuterolfenoterolformoterolhexoprenalineindacaterolisoetarineolodaterolpirbuterolprocaterolreproterolrimiterol show all 17 →

R03CC Selective beta-2-adrenoreceptor agonists 14 drugs

ambroxolbambuterolcarbuterolfenoterolformoterolhexoprenalineisoetarinepirbuterolprocaterolreproterolsalbutamolterbutaline show all 14 →

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

Species	Use	Relation
Horses	Management of horses affected with airway obstruction	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Ventipulmin Syrup	Boehringer lngelheim Animal Health USA Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.08	Basic
pKa2	1.84	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	7.16		DRUG MATRIX
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Kd	7.80		CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.82		DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	5.58		CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_BOVIN		Kd	7.44		CHEMBL

External reference:

ID	Source
N0000166810	NUI
D01360	KEGG_DRUG
235955	RXNORM
C0008932	UMLSCUI
CHEBI:174690	CHEBI
CHEMBL49080	ChEMBL_ID
DB01407	DRUGBANK_ID
CHEMBL1330729	ChEMBL_ID
D002976	MESH_DESCRIPTOR_UI
2783	PUBCHEM_CID
12582	IUPHAR_LIGAND_ID
3264	INN_ID
21898-19-1	SECONDARY_CAS_RN
XTZ6AXU7KN	UNII
004338	NDDF
004339	NDDF
1000821000202102	SNOMEDCT_US
418264008	SNOMEDCT_US
425138006	SNOMEDCT_US
XTZ6AXU7KN	INXIGHT DRUGS

Pharmaceutical products:

None